Brave Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Brave Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-50,817	Closed	-$490K	–	158
2020 Q4	$490K	Hold	50,817	–	–	0.19%	63
2020 Q3	$458K	Buy	+50,817	New	+$538K	0.22%	57
2020 Q1	–	Sell	-4,317	Closed	-$42K	–	156
2019 Q4	$42K	Buy	+4,317	New	+$38.5K	0.02%	152
2019 Q3	–	Sell	-14,852	Closed	-$137K	–	161
2019 Q2	$137K	Buy	+14,852	New	+$179K	0.08%	131
2016 Q4	–	Sell	-4,917	Closed	-$226K	–	311
2016 Q3	$226K	Sell	4,917 -3,750	-43%	-$196K	0.14%	117
2016 Q2	$435K	Buy	8,667 +2,925	+51%	+$156K	0.29%	79
2016 Q1	$307K	Hold	5,742	–	–	0.22%	99
2015 Q4	$377K	Sell	5,742 -1,200	-17%	-$74.2K	0.25%	92
2015 Q3	$392K	Sell	6,942 -550	-7%	-$35.7K	0.3%	85
2015 Q2	$443K	Hold	7,492	–	–	0.31%	86
2015 Q1	$467K	Hold	7,492	–	–	0.33%	79
2014 Q4	$431K	Buy	7,492 +242	+3%	+$13.5K	0.31%	85
2014 Q3	$390K	Sell	7,250 -400	-5%	-$21.2K	0.29%	92
2014 Q2	$401K	Hold	7,650	–	–	0.28%	99
2014 Q1	$404K	Sell	7,650 -300	-4%	-$13.9K	0.32%	86
2013 Q4	$319K	Buy	+7,950	New	+$313K	0.26%	93

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Brave Asset Management's TEVA Position: Q1 2021 in Review

Brave Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2021, closing a stake of 50,817 shares — an estimated $490K sold.

Brave Asset Management first reported a position in TEVA in Q4 2013 and held it in 16 quarters. The position peaked at $490K in Q4 2020. 451 funds tracked by Wall St. Rank hold TEVA as of Q1 2021.

Brave Asset Management reported no remaining Teva Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Brave Asset Management sold 50,817 Teva Pharmaceuticals shares in Q1 2021, an estimated $490K.
Brave Asset Management first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 16 quarters.
Brave Asset Management's Teva Pharmaceuticals position peaked at $490K in Q4 2020.
451 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2021.

Based on Brave Asset Management's 13F filing for Q1 2021, filed 26 Apr 2021.